Lista de obras - Frederik Persson - Dominio Público Uruguay

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study

artículo científico publicado en 2013

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

artículo científico publicado en 2013

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.

artículo científico publicado en 2012

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

publication published on 27 April 2022

Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria—A Path for Improved Renoprotection?

artículo científico publicado en 2018

Aliskiren combined with losartan in type 2 diabetes and nephropathy

artículo científico publicado en 2008

Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication

artículo científico publicado en 2009

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

artículo científico publicado en 2011

Ambulatory tonometric blood pressure measurements in patients with diabetes.

artículo científico publicado en 2012

Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes

artículo científico publicado en 2012

Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions

artículo científico publicado en 2020

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

article

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

artículo científico publicado en 2012

Cardiovascular and renal outcomes by baseline albuminuria status and renal function - results from the LEADER randomized trial

artículo científico publicado en 2020

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.

artículo científico

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

artículo científico publicado en 2018

Clinical use of estimated glomerular filtration rate for evaluation of kidney function

artículo científico publicado en 2013

Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases

artículo científico publicado en 2020

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.

artículo científico publicado en 2017

Development and validation of a brief, descriptive Danish pain questionnaire (BDDPQ).

artículo científico publicado en 2004

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

artículo científico publicado en 2015

Diagnosis of diabetic kidney disease: state of the art and future perspective ⬇️

artículo científico publicado en 2017

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

artículo científico publicado en 2018

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

artículo científico publicado en 2017

Direct renin inhibition in chronic kidney disease

artículo científico publicado en 2013

Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes

artículo científico publicado en 2012

Effect of large weight reductions on measured and estimated kidney function

scientific article published on 06 February 2017

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

artículo científico publicado en 2017

Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

artículo científico publicado en 2019

Effects of RAS inhibitors on diabetic retinopathy

artículo científico publicado en 2015

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial

artículo científico publicado en 2017

Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate

artículo científico publicado en 2011

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial.

artículo científico publicado en 2017

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

artículo científico publicado en 2008

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

artículo científico

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study.

artículo científico publicado en 2018

High YKL-40 levels predict mortality in patients with type 2 diabetes

artículo científico publicado en 2012

Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes

artículo científico publicado en 2017

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy

artículo científico publicado en 2011

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy ⬇️

artículo científico publicado en 2010

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study

artículo científico publicado en 2012

Implementation of proteomic biomarkers: making it work

artículo científico publicado en 2012

Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin

artículo científico publicado en 2019

Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment

artículo científico publicado en 2013

Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014.

artículo científico publicado en 2017

Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder

artículo científico publicado en 2019

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits

artículo científico publicado en 2017

Interpretation of HbA1c in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database

artículo científico publicado en 2018

Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial

artículo científico publicado en 2011

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

artículo científico publicado en 2006

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

artículo científico publicado en 2015

Is there any documentation for Lyrica in the treatment of painful diabetic neuropathy?

artículo científico publicado en 2005

Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

artículo científico publicado en 2012

Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy

artículo científico publicado en 2011

Microalbuminuria: a parameter that has changed diabetes care

artículo científico publicado en 2014

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

artículo científico publicado en 2014

Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial.

artículo científico publicado en 2016

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

artículo científico publicado en 2018

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial

artículo científico publicado en 2020

Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy

artículo científico publicado en 2015

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

artículo científico publicado en 2010

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial

artículo científico publicado en 2008

Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.

artículo científico publicado en 2017

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment

artículo científico publicado en 2019

Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.

artículo científico publicado en 2016

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

artículo científico publicado en 2017

Postural stability after inguinal herniorrhaphy under local infiltration anaesthesia

artículo científico publicado en 2001

Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.

artículo científico publicado en 2018

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.

artículo científico publicado en 2016

Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives

artículo científico publicado en 2018

Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria

scientific article published on 20 June 2019

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre

artículo científico publicado en 2016

Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).

artículo científico publicado en 2017

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

artículo científico publicado en 2009

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

artículo científico publicado en 2016

Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.

artículo científico publicado en 2016

Sequential RAAS blockade: is it worth the risk?

artículo científico

Serum uric acid and progression of diabetic nephropathy in type 1 diabetes

artículo científico publicado en 2018

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes

artículo científico publicado en 2019

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

artículo científico publicado en 2012

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria

artículo científico publicado en 2017

The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes

artículo científico publicado en 2019

The effect of liraglutide on renal function: A randomized clinical trial

artículo científico publicado en 2016

The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial.

artículo científico publicado en 2018

The effects of dapagliflozin, metformin or exercise on glycaemic variability in overweight or obese individuals with prediabetes (the PRE-D Trial): a multi-arm, randomised, controlled trial

artículo científico publicado en 2020

The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication

artículo científico publicado en 2015

Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment

artículo científico publicado en 2014

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

artículo científico publicado en 2008

Tissue Renin-Angiotensin systems: a unifying hypothesis of metabolic disease

artículo científico

Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria.

artículo científico publicado en 2017

Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes

artículo científico publicado en 2018

Urinary Proteomics and Precision Medicine for Chronic Kidney Disease: Current Status and Future Perspectives

scientific article published on 22 January 2019

Urinary albumin and 8-oxo-7,8-dihydroguanosine as markers of mortality and cardiovascular disease during 19 years after diagnosis of type 2 diabetes - A comparative study of two markers to identify high risk patients.

artículo científico publicado en 2017

Urinary proteomics for early diagnosis in diabetic nephropathy

artículo científico publicado en 2012

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study.

artículo científico publicado en 2016

Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?

artículo científico publicado en 2013

Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients

artículo científico publicado en 2018

Variability in response to albuminuria-lowering drugs: true or random?

artículo científico publicado en 2017

YKL-40 in dialysis patients: another candidate in the quest for useful biomarkers in nephrology.

artículo científico publicado en 2018

YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria

artículo científico publicado en 2008

[Renal disease by type 2 diabetes]

artículo científico publicado en 2012

initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial ⬇️

artículo científico publicado en 2011

Lista de obras de Frederik Persson

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus.

Acute and Long-Term Treatment With Dapagliflozin and Association With Serum Soluble Urokinase Plasminogen Activator Receptor

Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria—A Path for Improved Renoprotection?

Aliskiren combined with losartan in type 2 diabetes and nephropathy

Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

Ambulatory tonometric blood pressure measurements in patients with diabetes.

Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes

Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

Cardiovascular and renal outcomes by baseline albuminuria status and renal function - results from the LEADER randomized trial

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

Clinical use of estimated glomerular filtration rate for evaluation of kidney function

Comments on the 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases

Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study.

Development and validation of a brief, descriptive Danish pain questionnaire (BDDPQ).

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

Diagnosis of diabetic kidney disease: state of the art and future perspective ⬇️

Different patterns of second-line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study

Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function.

Direct renin inhibition in chronic kidney disease

Discrepancy Between Tonometric Ambulatory and Cuff-Based Office Blood Pressure Measurements in Patients With Type 1 Diabetes

Effect of large weight reductions on measured and estimated kidney function

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

Effects of RAS inhibitors on diabetic retinopathy

Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial

Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate

Empagliflozin reduces albuminuria-a promise for better cardiorenal protection from the EMPA-REG OUTCOME trial.

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study.

High YKL-40 levels predict mortality in patients with type 2 diabetes

Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy ⬇️

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study

Implementation of proteomic biomarkers: making it work

Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin

Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment

Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium-Glucose Cotransporter 2 Inhibitors-A Nationwide, Retrospective Cohort Study, 1995-2014.

Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits

Interpretation of HbA1c in primary care and potential influence of anaemia and chronic kidney disease: an analysis from the Copenhagen Primary Care Laboratory (CopLab) Database

Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.

Is there any documentation for Lyrica in the treatment of painful diabetic neuropathy?

Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

Long-term effects of Irbesartan treatment and smoking on nucleic acid oxidation in patients with type 2 diabetes and microalbuminuria: an Irbesartan in patients with type 2 diabetes and Microalbuminuria (IRMA 2) substudy

Microalbuminuria: a parameter that has changed diabetes care

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial.

N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post-hoc analysis from the randomized controlled PRE-D trial

Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial

Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy.

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment

Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Postural stability after inguinal herniorrhaphy under local infiltration anaesthesia

Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension.

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review.

Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives

Progressive Decline in Estimated Glomerular Filtration Rate in Patients With Diabetes After Moderate Loss in Kidney Function-Even Without Albuminuria

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre

Protocol for a randomised controlled trial of the effect of dapagliflozin, metformin and exercise on glycaemic variability, body composition and cardiovascular risk in prediabetes (the PRE-D Trial).

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes.

Sequential RAAS blockade: is it worth the risk?

Serum uric acid and progression of diabetic nephropathy in type 1 diabetes

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes